Results 71 to 80 of about 143,588 (347)

BRCA1/2 associated cancer susceptibility: a clinical overview

open access: yesForum of Clinical Oncology, 2016
The most frequently identified genetic cause of breast cancer is the germline mutation of BRCA1 and 2 genes. The carriers of these mutations are at high risk for breast and ovarian cancers and increased risk for pancreatic and prostate cancers.
Lypas Georgios
doaj   +1 more source

Developing a community-based breast cancer risk prediction tool for resource-poor settings

open access: yesJournal of Education and Health Promotion, 2019
BACKGROUND: With an estimation of every two women newly diagnosed with breast cancer, one dies. It is accounted that 1 in 28 women is likely to develop breast cancer during her lifetime.
Divya Pillai   +2 more
doaj   +1 more source

ОСОБЕННОСТИ ЭКСПРЕССИИ РЕЦЕПТОРОВ ЭСТРОГЕНОВ, ПРОГЕСТЕРОНА И АНДРОГЕНОВ ПРИ НАСЛЕДСТВЕННЫХ И СПОРАДИЧЕСКИХ ОВАРИАЛЬНЫХ КАРЦИНОМАХ

open access: yesŽurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2022
Введение. Овариальные карциномы – сложное гетерогенное заболевание с разнообразием клинико-морфологических форм. В большинстве случаев опухоли яичников экспрессируют эстрогеновые (РЭ), прогестероновые (РП) или андрогеновые (РА) рецепторы, но, в отличие ...
А. L. Savаnevich   +2 more
doaj   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

open access: yesMolecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric   +10 more
wiley   +1 more source

Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) [PDF]

open access: yes, 2003
INTRODUCTION: Ancestral mutations in BRCA1 and BRCA2 are common in people of Ashkenazi Jewish descent and are associated with a substantially increased risk of breast and ovarian cancer.
Ellen Solomon   +30 more
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

open access: yes, 2011
The associations of the 12 SNPs with risk for BRCA1 and BRCA2 carriers differ by ER-positive or ER-negative breast cancer status. The apparent differences in SNP associations between BRCA1 and BRCA2 carriers, and non-carriers, may be explicable by ...
Donaldson, A.   +999 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

BRCA1 and BRCA2 mutations in a population-based study of male breast cancer

open access: yes, 2001
Background: The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast ...
Bruce AJ Ponder   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy